Original Research J Clin Psychiatry March 2025

Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive Disorder

JCP 2025;86(1):10.4088/JCP.24m15449

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. Clinical Summary Patients with treatment-resistant depression often cycle through multiple antidepressant trials with limited remission and delayed benefit, so durability matters as much as initial response. This follow-up study asks a practical question for psychiatrists: after a single dose of psilocybin with psychological support, how long do benefits last, when do patients need additional treatment, and what safety issues emerge over 52 weeks? FAQ How long did benefits from a single dose of psilocybin last in treatment-resistant depression?

Key Takeaways In the prespecified analysis of all COMP 001 participants, median time to depression-related event was 92 days (49–199) with 25 mg, 83 days (39–142) with 10 mg, and 62 days (28–NE) with 1 mg, suggesting a dose-related separation in durability even though formal significance testing was not performed. Clinical Guide How should clinicians monitor for depressive relapse or recurrence after a single dose of psilocybin in treatment-resistant depression? Clinical Guide How can clinicians decide when additional depression treatment is needed after a single dose of psilocybin in treatment-resistant depression?